This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ji, Q. Articles by Stolz, A. Search for Related Content PubMed PubMed Citation Articles by Ji, Q. Articles by Stolz, A.

Selective Loss of AKR1C1 and AKR1C2 in Breast Cancer and Their Potential Effect on Progesterone Signaling

Departments of ¹ Medicine, ² Surgery, ³ Obstetrics and Gynecology, and ⁴ Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; and ⁵ Department of Pathology, Olive View-UCLA Medical Center, University of California Los Angeles, Sylmar, California

Progesterone plays an essential role in breast development and cancer formation. The local metabolism of progesterone may limit its interactions with the progesterone receptor (PR) and thereby act as a prereceptor regulator. Selective loss of AKR1C1, which encodes a 20-hydroxysteroid dehydrogenase [20-HSD (EC 1.1.1.149)], and AKR1C2, which encodes a 3-hydroxysteroid dehydrogenase [3-HSD (EC 1.1.1.52)], was found in 24 paired breast cancer samples as compared with paired normal tissues from the same individuals. In contrast, AKR1C3, which shares 84% sequence identity, and 5-reductase type I (SRD5A1) were minimally affected. Breast cancer cell lines T-47D and MCF-7 also expressed reduced AKR1C1, whereas the breast epithelial cell line MCF-10A expressed AKR1C1 at levels comparable with those of normal breast tissues. Immunohistochemical staining confirmed loss of AKR1C1 expression in breast tumors. AKR1C3 and AKR1C1 were localized on the same myoepithelial and luminal epithelial cell layers. Suppression of ARK1C1 and AKR1C2 by selective small interfering RNAs inhibited production of 20-dihydroprogesterone and was associated with increased progesterone in MCF-10A cells. Suppression of AKR1C1 alone or with AKR1C2 in T-47D cells led to decreased growth in the presence of progesterone. Overexpression of AKR1C1 and, to a lesser extent, AKR1C2 (but not AKR1C3) decreased progesterone-dependent PR activation of a mouse mammary tumor virus promoter in both prostate (PC-3) and breast (T-47D) cancer cell lines. We speculate that loss of AKR1C1 and AKR1C2 in breast cancer results in decreased progesterone catabolism, which, in combination with increased PR expression, may augment progesterone signaling by its nuclear receptors.

This article has been cited by other articles:

				K. W. Reding, C. I. Li, N. S. Weiss, C. Chen, C. S. Carlson, D. Duggan, K. E. Thummel, J. R. Daling, and K. E. Malone Genetic Variation in the Progesterone Receptor and Metabolism Pathways and Hormone Therapy in Relation to Breast Cancer Risk Am. J. Epidemiol., November 15, 2009; 170(10): 1241 - 1249. [Abstract] [Full Text] [PDF]

				A. Z. Steiner, L. Chang, Q. Ji, M. Ookhtens, A. Stolz, R. J. Paulson, and F. Z. Stanczyk 3{alpha}-Hydroxysteroid Dehydrogenase Type III Deficiency: A Novel Mechanism for Hirsutism J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1298 - 1303. [Abstract] [Full Text] [PDF]

				Q. Ji, L. Chang, F. Z. Stanczyk, M. Ookhtens, A. Sherrod, and A. Stolz Impaired Dihydrotestosterone Catabolism in Human Prostate Cancer: Critical Role of AKR1C2 as a Pre-Receptor Regulator of Androgen Receptor Signaling Cancer Res., February 1, 2007; 67(3): 1361 - 1369. [Abstract] [Full Text] [PDF]

				D. J. Yee, V. Balsanek, D. R. Bauman, T. M. Penning, and D. Sames Fluorogenic metabolic probes for direct activity readout of redox enzymes: Selective measurement of human AKR1C2 in living cells PNAS, September 5, 2006; 103(36): 13304 - 13309. [Abstract] [Full Text] [PDF]

				J. P Wiebe Progesterone metabolites in breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 717 - 738. [Abstract] [Full Text] [PDF]

				H. Lou, S. Du, Q. Ji, and A. Stolz Induction of AKR1C2 by Phase II Inducers: Identification of a Distal Consensus Antioxidant Response Element Regulated by NRF2 Mol. Pharmacol., May 1, 2006; 69(5): 1662 - 1672. [Abstract] [Full Text] [PDF]

				T. Suzuki, Y. Miki, Y. Nakamura, T. Moriya, K. Ito, N. Ohuchi, and H. Sasano Sex steroid-producing enzymes in human breast cancer Endocr. Relat. Cancer, December 1, 2005; 12(4): 701 - 720. [Abstract] [Full Text] [PDF]